Paratek Pharmaceuticals, Inc.
PRTK
PRTK was delisted on the 20th of September, 2023.
116 hedge funds and large institutions have $419M invested in Paratek Pharmaceuticals, Inc. in 2017 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 45 increasing their positions, 35 reducing their positions, and 28 closing their positions.
29% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 35
13% less funds holding
Funds holding: 133 → 116 (-17)
31% less capital invested
Capital invested by funds: $609M → $419M (-$190M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
57% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 28
59% less call options, than puts
Call options by funds: $1.12M | Put options by funds: $2.75M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$4.66M |
| 2 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
+$3.75M |
| 3 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$2.96M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$2.63M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$9.04M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.16M |
| 3 |
NC
Nexthera Capital
New York
|
-$6.08M |
| 4 |
HCM
Highbridge Capital Management
New York
|
-$5.29M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$3.83M |
PRTK Hedge Fund Activity: Q4 2017 in Review
116 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q4 2017, worth a combined $419M — down 31% from $609M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of PRTK and 12 opened new positions — a net loss of 16 holders — while 35 trimmed existing stakes and 45 added.
The largest buyer was Alyeska Investment Group, adding an estimated $4.66M. The largest seller was Franklin Resources, exiting entirely with an estimated $9.04M sold.
- 116 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q4 2017, down from 133 in Q3 2017.
- Funds reported $419M of Paratek Pharmaceuticals, Inc. stock for Q4 2017, down 31% quarter-over-quarter.
- 12 funds opened new Paratek Pharmaceuticals, Inc. positions in Q4 2017 and 28 closed out, a net change of -16 holders.
- The largest Paratek Pharmaceuticals, Inc. buyer in Q4 2017 was Alyeska Investment Group, an estimated $4.66M added.
- The largest Paratek Pharmaceuticals, Inc. seller in Q4 2017 was Franklin Resources, an estimated $9.04M sold.
Based on aggregated 13F filings for Q4 2017.